Bone Marrow Transplantation最新文献

{"title":"Wine without alcohol: medicine without doctors!","authors":"Shaun R McCann","doi":"10.1038/s41409-024-02421-0","DOIUrl":"https://doi.org/10.1038/s41409-024-02421-0","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity.","authors":"Saffiya Z Bashey, Scott R Solomon, Xu Zhang, Lawrence E Morris, H Kent Holland, Lizamarie Bachier, Krishi Patel, Melhem M Solh","doi":"10.1038/s41409-024-02417-w","DOIUrl":"https://doi.org/10.1038/s41409-024-02417-w","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary intake and risk of metabolic syndrome in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation","authors":"Louise Lindkvist Pedersen, Tina Gerbek, Maria Ebbesen Sørum, Ena Muhic, Terkel Christiansen, Karin Kok, Kaspar Sørensen, Christian Mølgaard, Klaus Müller","doi":"10.1038/s41409-024-02412-1","DOIUrl":"https://doi.org/10.1038/s41409-024-02412-1","url":null,"abstract":"<p>We explored the dietary intake and metabolic syndrome (MetS) in 85 survivors of pediatric stem cell transplantation (median age 30 years, median follow-up time 20 years). Overall, the distribution of fatty acid deviated from the recommendations with a higher intake of saturated fat and a lower intake of unsaturated fat but was comparable to that of the background population. The prevalence of MetS was 27%, corresponding to that of the elderly background population. We compared the intake of macronutrients between those with MetS and those without MetS and found that overall fat intake was higher in patients with MetS (36.7E% [range, 27.2–51.2E%] vs. 33,5E% (range, 23.4–45.1E%), <i>P</i> = 0.016). Within the subgroup of patients treated with total body irradiation (TBI), we found a higher fat intake in those with MetS (36.8E% (range, 27.2–51.2E%) versus 32.0E% (range, 24.6–42.1E%), <i>P</i> = 0.013). This was confirmed in a multivariate analysis adjusted for TBI, sex, and age at follow-up (OR 1.20 (1.06–1.39), <i>P</i> = 0.008). Our findings suggest that conditioning with the use of TBI may induce a state of hypersensitivity to the potentially harmful effects of fat in the diet and suggest that this risk of MetS after TBI treatment may be modifiable by dietary changes.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"3 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT","authors":"Clémence Aldebert, Mony Fahd, Jacques-Emmanuel Galimard, Ibrahim A. Ghemlas, Marco Zecca, Juliana Silva, Alexander Mohseny, Alphan Kupesiz, Rose-Marie Hamladji, Nuno Miranda, Tayfun Güngör, Robert F. Wynn, Pietro Merli, Mikael Sundin, Maura Faraci, Cristina Diaz-de-Heredia, Birgit Burkhardt, Victoria Bordon, Marie Angoso, Peter Bader, Marianne Ifversen, Concepcion Herrera Arroyo, Natalia Maximova, Susana Riesco, Jerry Stein, Arnaud Dalissier, Franco Locatelli, Krzysztof Kalwak, Jean-Hugues Dalle, Selim Corbacioglu","doi":"10.1038/s41409-024-02416-x","DOIUrl":"https://doi.org/10.1038/s41409-024-02416-x","url":null,"abstract":"<p>Congenital amegakaryocytic thrombocytopenia is a rare, inherited bone marrow failure syndrome. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In this retrospective study, we analysed 66 patients with allo-HSCT, reported in the European Society for Blood and Marrow Transplantation (EBMT) registry. Bone marrow (BM) was the most widely used stem cell source (<i>n</i> = 40; 61%) followed by peripheral blood (PB) (<i>n</i> = 18; 27%), and unrelated umbilical cord blood (UCB) (<i>n</i> = 8; 12%). Most frequently was a HLA-matched graft from related (<i>n</i> = 26; 39%) and unrelated (<i>n</i> = 15; 23%) donors after a myeloablative busulfan-based conditioning regimen. GvHD prophylaxis was mostly cyclosporine and methotrexate (53%). The 6-year cumulative incidence of graft-failure and second transplant were 25% and 17%, respectively. The 6-year disease-free survival (DFS) and overall survival (OS) were 66.9% and 85.6%, respectively. The 6-year transplant-related mortality (TRM) was 8.0%. In conclusion, most patients with CAMT benefit from allo-HSCT, but with many graft failures.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"9 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations","authors":"Gustavo C. Duarte, Leandro Ladvanszky, Gavin Atkinson, Michelle Burns, Dona Madola, Deepak Sadani, Marcus Yan-Fischer, Hemant Patel, Jacynthe Tremblay, Andrew Butler, Niranjan Rathod, Wen-Hua Wei","doi":"10.1038/s41409-024-02409-w","DOIUrl":"https://doi.org/10.1038/s41409-024-02409-w","url":null,"abstract":"<p>Impaired post-thaw CD34 cell (postCD34) viability in autologous haematopoietic stem cell transplant (ASCT) could indicate delayed engraftment where multiple factors might complicate the relationship. Despite of a couple of unconfirmed reports of a negative correlation of platelet concentration with postCD34 viability, how platelets might be involved in the relationship is largely unknown. Therefore, this question was addressed in this retrospective study of 82 ASCT patients with a total of 150 collections of peripheral blood stem cells in New Zealand. A significant negative correction between platelet concentration and postCD34 recovery (r = −0.18, <i>p</i> = 0.028) was observed overall, but upon further analysis only confirmed in the subset with graft platelets 1500–2000 ×10⁹/L. Importantly, the postCD34 recovery was clearly reduced in the subgroups with either the lowest or the highest platelet concentration. The lowest subgroup was enriched with collections from patients with Hodgkin or non-Hodgkin lymphoma, whereas the highest subgroup from patients with multiple myeloma, both with clearly male preponderance. We hypothesized that graft platelet concentrations probably indicated CD34 cell state (e.g. cell cycle and cell adhesion highly related to platelet functions) that sustained when platelet concentrations were within a niche range but went out of kilter otherwise.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"190 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC","authors":"María Queralt Salas, Enric Cascos, Alberto López-García, Estefanía Pérez-López, Mónica Baile-González, Lucía López-Corral, María Jesús Pascual Cascón, Marta Luque, Albert Esquirol, Inmaculada Heras Fernando, Itziar Oiartzabal Ormtegi, Adolfo Jesús Sáez Marín, Felipe Peña-Muñóz, Sara Fernández-Luis, Juan José Domínguez-García, Sara Villar Fernández, Miguel Fernández de Sanmamed Girón, Leslie González Pinedo, Ana Pilar González-Rodríguez, Tamara Torrado, Lucía García, Silvia Filaferro, Ángel Cedillo, Pascual Basalobre, Guillermo Ortí, Manuel Jurado Chacón","doi":"10.1038/s41409-024-02414-z","DOIUrl":"https://doi.org/10.1038/s41409-024-02414-z","url":null,"abstract":"<p>This multicenter study investigates the incidence and predictors of cardiac events (CE) following allo-HCT with PTCY in 453 AML patients. CE occurred in 57 (12.3%) patients within a median of 52 days (IQR: 13–289), with day 100 and 5-year cumulative incidences of 7.7% and 13.5%. Early (first 100 days) and late CE occurred at rates of 7.7% and 4.8%. The most prevalent CE were heart failure (<i>n</i> = 18, 31.6%), pericardial complications (<i>n</i> = 16, 28.1%), and arrhythmia (<i>n</i> = 14, 24.6%). The proportions of patients older than 55 years (64.9% vs. 46.1%, <i>P</i> = 0.010), with hypertension (36.8% vs. 18.4%, <i>P</i> = 0.001) and dyslipidemia (28.1% vs. 11.1%, <i>P</i> = 0.001) were higher in patients with CE. Patients undergoing haplo-HCT trend to have more CE (68.4% vs. 56.8%, <i>P</i> = 0.083). The multivariate regression analysis revealed that only hypertension (HR 1.88, <i>P</i> = 0.036) and dyslipidemia (HR 2.20, <i>P</i> = 0.018) were predictors for CE, with no differences according to donor type (haplo-HCT vs. others: HR 1.33, <i>P</i> = 0.323). Among the 57 patients with CE, the mortality rate was 12.2%. Notably, the diagnosis of CE negatively impacted NRM (HR 2.57, <i>P</i> = 0.011) and OS (HR 1.80, <i>P</i> = 0.009), underscoring necessity of aggressively treating cardiovascular risk factors, and implementing post-transplant cardiac monitoring protocols to prevent these complications.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"30 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","authors":"Vera Domingos, Katerina Nezvalova-Henriksen, Adrin Dadkhah, Maria-Estela Moreno-Martinez, Khalil Ben Hassine, Vera Pires, Nicolaus Kröger, Tiene Bauters, Moustapha Hassan, Nick Duncan, Krzysztof Kalwak, Marc Ansari, Claudia Langebrake, Rick Admiraal","doi":"10.1038/s41409-024-02413-0","DOIUrl":"https://doi.org/10.1038/s41409-024-02413-0","url":null,"abstract":"<p>Busulfan (Bu) is an important component of many conditioning regimens for allogeneic hematopoietic cell transplantation. The therapeutic window of Bu is well characterized, with strong associations between Bu exposure and the clinical outcome in adults (strongest evidence in myelo-ablative setting) and children (all settings). We provide an overview of the literature on Bu as well as a step-by-step guide to the implementation of Bu therapeutic drug monitoring (TDM). The guide covers the clinical, pharmacological, laboratory and administrative aspects of the procedure. Through this document, we aim to support centers in implementing TDM for Bu to further enhance the success rates of HCT and improve patient outcomes. The Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT) encourages all centers to perform TDM for Bu in the aforementioned indications.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"18 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive multifocal leukoencephalopathy after CAR-T cell therapy","authors":"Michael Montoya, Hannah J. Harmsen, Brittney Baer, Nancy Long, Amy Messimore, Reena V. Jayani, Adetola Kassim, Andrew P. Jallouk, James Jerkins, Eden A. Biltibo, Bipin N. Savani, Bhagirathbhai Dholaria, Olalekan Oluwole, David S. Morgan","doi":"10.1038/s41409-024-02410-3","DOIUrl":"https://doi.org/10.1038/s41409-024-02410-3","url":null,"abstract":"<p>Progressive multifocal leukoencephalopathy (PML) is a rare and devastating viral infection that affects the central nervous system (CNS) of severely immunocompromised patients. Lymphodepletion followed by chimeric antigen receptor T cell (CAR-T) therapy to treat certain hematologic malignancies can result in prolonged immunocompromised status. The recipients of CAR-T therapy are at risk of opportunistic infections including progressive multifocal leukoencephalopathy (PML). CAR-T therapy itself is associated with early and late neurotoxicities and can make the diagnosis of PML difficult [1]. Given its high mortality rate (30–50%) in the first few months following initial diagnosis, early rapid diagnosis is important to prevent permanent neurological damage [2]. Here, we discuss a case of PML in a patient with relapsed diffuse large B cell lymphoma (DLBCL) two years after the CD19 CAR-T therapy. We have also provided a table summary of four other published cases of PML after CAR-T therapy and reviewed relevant literature on the management.</p><p>A 73-year-old female with DLBCL, refractory to R-CHOP and lenalidomide and Revlimid was referred for CD19-directed CAR-T therapy. She received fludarabine and cyclophosphamide (Flu/Cy) lymphodepletion followed by axicabtagene ciloleucel (axi-cel, CD19-directed CAR-T therapy) on the ZUMA-1 clinical trial (NCT02348216). Early complications included grade 2 cytokine release syndrome (CRS) and grade 2 immune effector cell neurotoxicity syndrome (ICANS). She received tocilizumab and dexamethasone, with a resolution of these side effects. Subsequent PET/CT scan showed complete remission. She developed persistent hypogammaglobulinemia following CAR-T and was treated with intravenous immunoglobulin (IVIG). She also developed COVID-19 infection twice (6 months and 9 months) after axi-cel, for which she was treated with hydroxychloroquine and convalescent plasma.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"20 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142215830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation","authors":"Phuong Vo, Ramaprasad Srinivasan, Enkhtsetseg Purev, Emily McDuffee, Tatyana Worthy, Reem Shalabi, Kristen Wood, Brian Wells, Robert Reger, David Stroncek, Nancy Geller, Georg Aue, Xin Tian, Richard Childs","doi":"10.1038/s41409-024-02380-6","DOIUrl":"https://doi.org/10.1038/s41409-024-02380-6","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"15 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142215831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review and meta-analysis of HHV-6 and mortality after hematopoietic cell transplant.","authors":"Christopher J Stathis, Harrison Zhu, Kristen Carlin, Tuan L Phan, Danny Toomey, Joshua A Hill, Danielle M Zerr","doi":"10.1038/s41409-024-02398-w","DOIUrl":"https://doi.org/10.1038/s41409-024-02398-w","url":null,"abstract":"<p><p>Human herpesvirus-6B (HHV-6B) reactivation has been associated with non-relapse mortality (NRM) and overall mortality (OM) following allogeneic hematopoietic stem cell transplant (HCT). We performed a systematic review and meta-analysis to better quantify the association. Studies were included if they systematically tested a cohort of HCT recipients for HHV-6 infection or reactivation and described mortality for patients with and without HHV-6B. Random effects models were used to assess the pooled effect of HHV-6B positivity on each outcome of interest. Bayesian aggregation was additionally performed if models included 10 or fewer studies. Eight studies were included in the NRM analysis, which demonstrated a significant association between HHV-6 detection and NRM (pooled effect: 1.84; 95% CI: 1.29-2.62) without significant heterogeneity (I² = 0.0%, p = 0.55). A Bayesian aggregation of the raw data used to construct the NRM random effects model supported these findings (95% credible interval: 0.15-1.13). Twenty-five studies were included in OM analysis, which showed a significant positive association (pooled effect: 1.37; 95% CI: 1.07-1.76), though considerable heterogeneity was observed (I² = 36.7%, p < 0.05). HHV-6 detection is associated with NRM and OM following HCT. Randomized trials are warranted to evaluate if preventing or treating HHV-6B reactivation improves outcomes.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}